Bristol-myers Squibb Compnay

Xiaojun Han

Gene Michael Dubowchik

John E Macor

R Michael Lawrence

Dasa Lipovsek

Prasad V Chaturvedula

Claudio Mapelli

Paul E Morin

Rita Civiello

Michael C Myers

Cort S Madsen

Olafur S Gudmundsson

Guanglin Luo

Graham S Poindexter

Andrew P Degnan

George O Tora

Ling Chen

Xiang Jun J Jiang

Pratik Devasthale

Guohua Zhao

Michael Frederick Parker

Stephen E Mercer

Xiang-Yang Ye

Kumaravel Selvakumar

Suresh Dhanusu

George N Karageorge

Swanee E Jacutin-Porte

Leatte R Guernon

Palanikumar Balasubramanian

Haiquan Fang

Shikha Vig

Charles Mark Conway

The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.

Methods of treating kidney failure, and/or improving or stablizing renal function using modified relaxin polypeptides

Treatment of fibrosis, cardiovascular disease and heart failure with modified relaxin polypeptides

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to α-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of α-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

3-substituted propionic acids as αV integrin inhibitors

Modified relaxin polypeptides comprising a pharmacokinetic enhancer and pharmaceutical compositions thereof

Method of treating cardiovascular disease and heart failure with modified relaxin polypeptides

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to &#x3b1;-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of ay-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions. 

3-substituted propionic acids as &#x3b1;V integrin inhibitors

Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof

The present invention relates to compounds of Formula (I) as antagonists of calcitonin gene-related peptide receptors ('CGRP-receptor'), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

Anti-migraine spirocycles

The present invention encompasses compounds of Formula I 

CGRP antagonists

Therapeutic agents for the treatment of migraine

The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists, methods for identifying them, pharmaceutical compositions comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors. 

Constrained compounds as CGRP-receptor antagonists

The present invention relates to methods of treating neurogenic vasodilation, neurogenic inflammaton, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors using pharmaceutical compositions comprising compounds of Formula (I) 

Anti-migraine treatments

The present invention relates to novel heterocyclic antagonists of Formula (I) and pharmaceutical compositions comprising said antagonists of the corticotropin releasing factor receptor ('CRF receptor') useful for the treatment of depression, anxiety, affective disorders, feeding disorders, post-traumatic stress disorder, headache, drug addiction, inflammatory disorders, drug or alcohol withdrawal symptoms and other conditions the treatment of which can be effected by the antagonism of the CRF-1 receptor.

Imidazolyl derivatives as corticotropin releasing factor inhibitors

Calcitonin gene related peptide receptor antagonists

Growing community of inventors

Cheshire, CT, United States of America

Xiaojun Han